Licensing status

Publication and contact information


Non-small cell lung cancer (NSCLC)

Peroxisome proliferation-activated receptor-a (PPARA; PPARa)

Mouse studies suggest PPARa agonists could help treat NSCLC. In transgenic mice that develop spontaneous NSCLC tumors, a PPARa ligand decreased tumor size, number and vascularization by decreasing the expression and activity of cytochrome P450 family 2
subfamily C polypeptide 44
(Cyp2c44) and levels of proangiogenic epoxyeicosatrienoic acids (EETs) compared with vehicle. Also in mice, PPARa-activating ligands including bezafibrate decreased primary tumor growth and metastasis of human NSCLC cells injected into the lung parenchyma. Next steps could include testing bezafibrate in additional models of NSCLC.
Bezafibrate and other generic PPARa agonists are marketed to treat dyslipidemia.

SciBX 7(3); doi:10.1038/scibx.2014.86
Published online Jan. 23, 2014

Patent and licensing status unavailable

Skrypnyk, N. et al. Cancer Res.; published online Dec. 3, 2013;
Contact: Ambra Pozzi, Vanderbilt University School of Medicine, Nashville, Tenn.